高尿酸血症 中国就医指南

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid (SUA) levels—defined as >6.8 mg/dL (>405 µmol/L) in men and >5.7 mg/dL (>340 µmol/L) in women—reflecting an imbalance between uric acid production and renal excretion. Uric acid is the end product of purine metabolism in humans; unlike most mammals, humans lack uricase, making them prone to urate accumulation. Pathogenesis involves either overproduction (e.g., due to increased purine synthesis, high dietary purine intake, or enzymatic defects like HGPRT deficiency), underexcretion (accounting for ~90% of cases, often linked to reduced URAT1 or GLUT9 transporter activity in proximal renal tubules), or a combination. Genetic factors—including polymorphisms in SLC2A9, ABCG2, and SLC22A12—significantly influence urate handling. Secondary causes include chronic kidney disease, hypertension, obesity, metabolic syndrome, diuretic use (especially thiazides and loop diuretics), alcohol consumption (particularly beer and spirits), and malignancy-related tumor lysis. Epidemiologically, hyperuricemia affects approximately 14–24% of adults globally, with rising prevalence in China (13.3% overall, up to 21.6% in urban males aged 40–60), driven by aging, dietary Westernization, sedentary lifestyles, and increasing rates of obesity and CKD. Key modifiable risk factors include high-fructose corn syrup intake (e.g., sugary beverages), red meat and seafood consumption, excessive alcohol, insulin resistance, and chronic low-grade inflammation. Non-modifiable risks include male sex, postmenopausal status, family history, and certain ethnic backgrounds (e.g., East Asian and Pacific Islander populations show higher baseline SUA). Although often asymptomatic, persistent hyperuricemia substantially elevates the risk of gout (acute inflammatory arthritis), uric acid nephrolithiasis, chronic kidney disease progression, cardiovascular morbidity (including hypertension, coronary artery disease, and heart failure), and metabolic dysfunction. Quality of life is frequently impaired—even before gout onset—due to anxiety about flare unpredictability, dietary restrictions limiting social engagement, chronic fatigue, sleep disruption from nocturnal flares, and stigma associated with visible tophi or recurrent joint swelling. Untreated, it contributes to long-term disability, work absenteeism, and reduced physical function. Early detection via routine serum uric acid screening—especially in patients with hypertension, diabetes, CKD, or metabolic syndrome—is critical for timely intervention and prevention of irreversible organ damage.

# 高尿酸血症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：无症状高尿酸血症（SU > 420 μmol/L）、痛风间歇期、合并轻度肾功能不全（eGFR ≥ 60 mLm²）者。

• •生活方式干预（免费–300元/年）：营养科门诊280元/次）、运动处方（含体脂分析+代谢评估，200元/次）
• •降尿酸药物治疗（首年总费用）：

- 替代（非布司他）：检查同上；药费（3–6个月）1,800–3,600元 - 尿酸酶类（培格洛替酶，限单次静脉输注 12,000–15,000元（需每月1次，医保限适应证）

二、手术/介入方案

高尿酸血症本身无需手术；仅当并发、关节破坏或肾结石梗阻时，由泌尿外科/骨科协同处理，内分泌科主导围术期尿酸管理。

• •痛风石清除术（关节镜/开放）：术前检查（CT+尿酸+24h尿尿酸）620元；手术费+麻醉+住院（7天）18,000–35,00尿管镜碎石术（尿酸结石）：术前检查同上；全套费用22,000–42,000元

三、复杂/晚期方案

适用：慢性痛风性肾病（CKD 3–4期）、多发痛风石、药物不耐受或抵抗者。

• •多学科联合管理（内分泌+肾内科+营养科）：年度随访套餐（含尿酸谱、肾小球滤过率动态监测、痛风活动评分）4,200–6,500元
• •血液灌流/吸附降尿酸（超适应证）：单次治疗3,800–5,200元，限eGFR < 30 mL/min且药物无效者

方案快速选择指南

• •预算有限/初诊者：首选别嘌醇+生活方式干预（首年总支出 ≤ 2,000元）
• •中等预算/反复发作：非布司他+规范随访（首年约5,000–8,000元）
• •晚期/并发症者：MDT管理+必要外科干预（年度支出 ≥ 30,000元，医保报销后自付约30%–50%）